NCT07412314 Proton Therapy for Recurrent Nasopharyngeal Carcinoma
| NCT ID | NCT07412314 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangzhou Concord Cancer Center |
| Condition | Recurrent Nasopharyngeal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 52 participants |
| Start Date | 2025-03-10 |
| Primary Completion | 2028-03-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 52 participants in total. It began in 2025-03-10 with a primary completion date of 2028-03-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The above studies show that most of the supportive evidence for the reduction of toxicity and improvement of efficacy of proton therapy for recurrent Nasopharyngeal carcinoma(NPC) comes from various observational and retrospective studies, lacking high-level evidence-based medical evidence. The conduct of this study will explore the safety and efficacy of intensity-modulated proton radiotherapy for recurrent NPC and provide more high-quality evidence-based medical evidence for proton therapy of recurrent cancer.
Eligibility Criteria
Inclusion Criteria: 1. Non-metastatic squamous cell carcinoma of the nasopharynx with biopsy confirmation, at stage ≥ T2b and/or with positive lymph nodes, (2) Pathological type WHO I-III 2. PS score (according to Eastern Cooperative Oncology Group (ECOG) standard) 0-1. Age ≥ 18 years. 3. Expected survival period ≥ 6 months 4. Before treatment, evaluate the tumor range and size of the patient. 5. Nutritional and general physical condition must be able to tolerate the recommended radiotherapy and chemotherapy. Exclusion Criteria: 1. Evidence of distant metastasis in stage IVc 2. Patients with isolated recurrence of cervical lymph nodes; 3. Patients have participated in other interventional trials for tumors 4. Having suffered from other malignant tumors within 5 years (excluding melanoma skin cancer) or tumors originating from the head and neck region Untreated active infections
Contact & Investigator
Yuan Taize
STUDY DIRECTOR
private hospital
Frequently Asked Questions
Who can join the NCT07412314 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Recurrent Nasopharyngeal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07412314 currently recruiting?
Yes, NCT07412314 is actively recruiting participants. Contact the research team at taize.yuan@ccm.cn for enrollment information.
Where is the NCT07412314 trial being conducted?
This trial is being conducted at Guangzhou, China, Guanzhou, China.
Who is sponsoring the NCT07412314 clinical trial?
NCT07412314 is sponsored by Guangzhou Concord Cancer Center. The principal investigator is Yuan Taize at private hospital. The trial plans to enroll 52 participants.